H
Hubei Goto Biopharm Co Ltd
SZSE:300966
Hubei Goto Biopharm Co Ltd
SZSE:300966
Price:
20.35
CNY
8.94%
Market Closed
Market Cap:
¥2.3B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
H
|
Hubei Goto Biopharm Co Ltd
SZSE:300966
|
CN |
|
C
|
Cdon AB
STO:CDON
|
SE |
|
A
|
Aseed Holdings Co Ltd
TSE:9959
|
JP |
|
A
|
Arabian Drilling Co
SAU:2381
|
SA |
|
Suzhou Anjie Technology Co Ltd
SZSE:002635
|
CN |
|
Thungela Resources Ltd
LSE:TGA
|
ZA |
|
Akshar Spintex Ltd
NSE:AKSHAR
|
IN |
|
I
|
Imagis Co Ltd
KOSDAQ:115610
|
KR |
|
Transgene SA
PAR:TNG
|
FR |
|
Samsung SDS Co Ltd
KRX:018260
|
KR |
|
Ventas Inc
NYSE:VTR
|
US |
|
S
|
SCI JSC
VN:S99
|
VN |
Relative Value
The Relative Value of one Hubei Goto Biopharm Co Ltd stock under the Base Case scenario is hidden CNY. Compared to the current market price of 20.35 CNY, Hubei Goto Biopharm Co Ltd is hidden .
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
Hubei Goto Biopharm Co Ltd Relative Value
HIDDEN
Multiples Across Competitors
Competitors Multiples
Hubei Goto Biopharm Co Ltd Competitors
Hubei Goto Biopharm Co Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CN |
H
|
Hubei Goto Biopharm Co Ltd
SZSE:300966
|
2.3B CNY | 3.7 | -51.1 | -155.2 | -155.2 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
366.3B USD | 6 | 87.5 | 14.5 | 20.2 | |
| US |
|
Exact Sciences Corp
NASDAQ:EXAS
|
355.9B USD | 109.6 | -1 710.6 | 15 890.6 | -1 794.3 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
190.8B USD | 5.2 | 24.7 | 14.3 | 14.3 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
171.4B USD | 5.8 | 20.2 | 12.6 | 15.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
113.9B USD | 9.6 | 29.2 | 22 | 23 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78.4B USD | 5.5 | 17.6 | 13 | 14.9 | |
| AU |
|
CSL Ltd
ASX:CSL
|
67.2B AUD | 3.1 | 34.4 | 11.4 | 14.3 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
